



Aarti Drugs Limited

Manufacturers of : Bulk Drugs & Chemicals

Corporate Office : Mahendra Industrial Estate,
Ground Floor, Plot No. 109-D, Road No. 29,
Sion (East), Mumbai - 400 022. (India)
Tel.: 022-2407 2249 / 2401 9025 (30 Lines)
Fax: 022-2407 3462 / 2407 0144
Email: audit@aartidrugs.com
website: www.aartidrugs.com
CIN No.: L37060MH1984PLC055433

Ref. No: ADL/SE-2M2016

Date : 5th February, 2016

To,
Listing/Compliance Department
BSE LTD.

Phiroze Jeejeebhoy Towers,
Dalal Street,
Mumbai – 400 001.

BSE CODE –524348

To,
Listing/Compliance Department
**National Stock Exchange of
India Limited**

“Exchange Plaza”, Plot No. C/1,
G Block Bandra-Kurla Complex,
Bandra (E), Mumbai – 400 051.

NSE CODE:AARTIDRUGS

Dear Sir/Madam,

Ref.: Compliance of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements), Regulations, 2015.

Sub : Audited Financial Results for the quarter & nine months ended 31st December, 2015.

Pursuant to Regulation 33 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements), Regulations, 2015, we are forwarding herewith the Audited Financial Results along with Auditor's Report on Quarterly Financial Results of the Company for the quarter & nine months ended 31st December, 2015 in the prescribed form which have been taken on record by the Board of Directors of the Company at its meeting held on **Friday, 5th February, 2016** at Indore.

Further, please note that the Company has already made necessary arrangement to publish the same in the newspapers as required under SEBI (Listing Obligations and Disclosure Requirements), Regulations, 2015.

Please take note of the same on your record.

Thanking you,

Yours faithfully,
For **AARTI DRUGS LIMITED**

HARSHIT M. SAVLA
JT. MANAGING DIRECTOR
Encl: as above.



Aarti Drugs Limited

Manufacturers of : Bulk Drugs & Chemicals

Corporate Office : Mahendra Industrial Estate,
Plot No. 109-D, Road No. 29, Sion (East),
Mumbai - 400 022. (India)
Tel.: 022-2407 2249 / 2401 9025 (30 Lines)
Fax : 022-2407 3462 / 2407 0144
Email : admin@aartidrugs.com
Website : www.aartidrugs.com
CIN NO : L37060MH1984PLC055433

AARTI DRUGS LIMITED										
STATEMENT OF AUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED 31ST DEC, 2015										
(Rs. in lacs except for share data)										
PART I		Standalone					Consolidated			
Sr. No.	Particulars	Quarter Ended			Period Ended		Year Ended		Quarter Ended	
		31st Dec 2015	30th Sep 2015	31st Dec 2014	31st Dec 2015	31st Dec 2014	31st Mar 2015	31st Dec 2014	31st Dec 2015	31st Mar 2015
		(Audited)	(Audited)	(Audited)	(Audited)	(Audited)	(Audited)	(Audited)	(Audited)	(Audited)
1	Income from Operations									
	(a) Gross Sales / Income from Operations	27,619	27,975	28,119	84,234	86,744	1,16,994	28,799	29,455	88,856
	Less : Excise Duty & Sales Tax	2,322	2,223	2,161	6,855	6,239	8,546	2,299	2,191	6,764
	(a) Net Sales / Income from Operations (Net Of Excise Duty & Sales Tax)	25,297	25,752	25,958	77,378	80,505	1,08,448	26,499	27,264	82,092
	(b) Other Operating Income	375	13	150	425	199	274	367	20	431
	Total income from operations (net)	25,672	25,765	26,107	77,804	80,704	1,08,722	26,867	27,283	82,523
2	Expenditure									
	(a) Cost of materials consumed	14,942	18,571	17,638	52,492	52,031	67,844	15,424	19,213	55,398
	(b) Purchase of stock-in-trade	475	1,128	1,602	2,574	7,524	8,699	911	1,752	3,596
	(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	1,109	(2,704)	(1,964)	(4,076)	(4,496)	(2,358)	1,140	(2,687)	(4,014)
	(d) Employee benefits expense	1,017	1,006	918	3,017	2,706	3,730	1,098	1,091	3,254
	(e) Depreciation and Amortisation Expense	900	885	771	2,651	2,258	3,066	922	907	2,717
	(f) Other expenses	3,885	3,562	3,536	11,000	10,333	13,911	3,979	3,658	11,295
	Total expenses	22,328	22,448	22,500	67,658	70,356	94,893	23,474	23,934	72,247
3	Profit from Operations before Other Income, finance costs and exceptional items (1-2)	3,344	3,317	3,608	10,145	10,348	13,829	3,393	3,349	10,276
4	Other Income	-	-	64	-	64	65	-	-	65
5	Profit from ordinary activities before finance cost and exceptional items (3+4)	3,344	3,317	3,672	10,145	10,413	13,894	3,393	3,349	10,276
6	Finance costs (interest)	1,108	1,066	986	3,203	2,912	3,888	1,115	1,078	3,237
7	Profit from ordinary activities after finance cost but before Exceptional Items (5-6)	2,236	2,251	2,686	6,942	7,501	10,006	2,278	2,271	7,038
8	Exceptional Items	-	-	-	-	-	-	-	-	-
9	Profit from Ordinary Activities before Tax (7-8)	2,236	2,251	2,686	6,942	7,501	10,006	2,278	2,271	7,038
10	Tax Expenses	575	700	411	2,025	1,626	2,247	575	700	2,025
	Provision for Taxation - Current	435	580	495	1,625	1,572	2,100	435	580	1,625
	- MAT Credit Entitlement	-	-	(31)	-	(52)	(100)	-	-	(100)
	- Earlier year	-	-	(153)	-	(153)	(153)	-	-	(153)
	Provision for Deferred Taxation	140	120	100	400	260	400	140	120	400
11	Net profit from ordinary Activities after Tax (9-10)	1,661	1,551	2,275	4,917	5,874	7,760	1,703	1,571	5,013
12	Extraordinary items	-	-	-	-	-	-	-	-	-
13	Net Profit for the Period (11+12)	1,661	1,551	2,275	4,917	5,874	7,760	1,703	1,571	5,013
14	Shares of Profit/ (Loss) of associates	-	-	-	-	-	-	-	-	-
15	Minority Interest	-	-	-	-	-	-	-	-	-
16	Net Profit for the Period after taxes, minority interest and share of profit/ (loss) of associates (13+14+15)	1,661	1,551	2,275	4,917	5,874	7,760	1,703	1,571	5,013
17	Paid-up Equity Share Capital of Rs.10/- each.	2,422	2,422	1,211	2,422	1,211	2,422	2,422	2,422	2,422
18	Reserves & Surplus (excluding revaluation reserves)	-	-	-	-	-	27,949	-	-	28,394
19	Earning per share									
	Diluted EPS (in Rs.)									
	(of Rs. 10/- each) (not annualised)									
	(a) Basic & Diluted (before extraordinary items)	6.86	6.41	9.40	20.31	24.26	32.04	7.03	6.49	20.70
	(b) Basic & Diluted (after extraordinary items)	6.86	6.41	9.40	20.31	24.26	32.04	7.03	6.49	20.70

* EPS has been adjusted for previous periods as per Accounting Standard 20 on Earning Per Share considering bonus equity shares allotment made by the Company in the proportion of 1:1 on 26th March, 2015.

Notes :

- The above results for the quarter and nine months ended 31st December, 2015 have been reviewed by the Audit Committee and approved by the Board of Directors in their meeting held on 5th February, 2016.
- The Board of Directors have declared 2nd Interim Dividend of Rs.1.50/- per Equity Share of Rs. 10/- each (15%) amounting to Rs.3,63,25,650/- and 15th February, 2016 has been Fixed as Record Date for the payment of the said 2nd Interim Dividend.
- The company has published consolidated financial Results from Quarter Ended September, 2015 in addition to stand alone Results, pursuant to decision taken by Board of Director in its Meeting held on July 31, 2015, As a results the audited Financial Results of its only subsidiary, Pinnacle Life science Pvt. Ltd., for the Quarter Ended September 30, 2015 and December 31, 2015 has been included.
- Company is operating as a single segment company, engaged in pharmaceutical Business.
- Figures for the previous period have been regrouped or rearranged wherever necessary.
- The aforesaid Audited Financial Results will be uploaded on the Company's website www.aartidrugs.com and will also be available on the website of BSE Limited www.bseindia.com and the National Stock Exchange of India Limited www.nseindia.com for the benefit of the shareholders and investors.

For AARTI DRUGS LIMITED

HARSHIT M. SAVLA
JT. MANAGING DIRECTOR

Place: Indore

Date: 5th February, 2016



gokhale & sathe

(regd.)

chartered accountants

308/309, udyog mandir no. 1,
7-c, bhagoji keer marg,
mahim, mumbai 400 016


Auditor's Report on Quarterly Financial Results and Year to Date Results of AARTI DRUGS LIMITED Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

To

The Board of Directors of AARTI DRUGS LIMITED

We have audited the quarterly financial results of AARTI DRUGS LIMITED ('the Company') for the quarter ended December 31, 2015 and the year to date financial results for the period from April 1, 2015 to December 31, 2015, attached herewith, being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. These quarterly financial results as well as the year to date financial results have been prepared on the basis of the interim financial statements, which are the responsibility of the company's management. Our responsibility is to express an opinion on these financial results based on our audit of such interim financial statements, which have been prepared in accordance with the recognition and measurement principles laid down in Accounting Standard (AS) 25, on Interim Financial Reporting, specified under section 133 of the Companies Act, 2013 read with Rule 7 of the Companies (Accounts) Rules, 2014 and other accounting principles generally accepted in India.

We conducted our audit in accordance with the auditing standards generally accepted in India. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial results are free of material misstatement(s). An audit includes examining, on a test basis, evidence supporting the amounts disclosed as financial results. An audit also includes assessing the accounting principles used and significant estimates made by management. We believe that our audit provides a reasonable basis for our opinion.






In our opinion and to the best of our information and according to the explanations given to us these quarterly financial results as well as the year to date financial results:

- (i) are presented in accordance with the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015 in this regard; and
- (ii) give a true and fair view of the net profit and other financial information for the quarter ended December 31, 2015 and year to date results for the period from April 1, 2015 to December 31, 2015.

For GOKHALE & SATHE
CHARTERED ACCOUNTANTS
Firm Registration No.: 103264W

TEJAS. J. PARIKH
PARTNER
M. No. 123215
Place: Indore
Date: February 5, 2016.





gokhale & sathe

(regd.)

chartered accountants

308/309, udyog mandir no. 1,
7-c, bhagoji keer marg,
mahim, mumbai 400 016.


**Auditors' Report on Quarterly Consolidated Financial Results and Year to Date
Consolidated Financial Results of AARTI DRUGS LIMITED Pursuant to the
Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements)
Regulations, 2015**

To

Board of Directors of AARTI DRUGS LIMITED.

We have audited the quarterly consolidated financial results of AARTI DRUGS LIMITED ("the Company") for the quarter ended December 31, 2015, and the year to date consolidated financial results for the period from April 1, 2015 to December 31, 2015 attached herewith, being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. These quarterly consolidated financial results as well as the year to date consolidated financial results have been prepared from consolidated interim financial statements, which are the responsibility of the Company's management. Our responsibility is to express an opinion on these consolidated financial results based on our audit of such consolidated interim financial statements, which have been prepared in accordance with the recognition and measurement principles laid down in Accounting Standard (AS) 25, on Interim Financial Reporting, specified under section 133 of the Companies Act, 2013 read with Rule 7 of the Companies (Accounts) Rules, 2014 and other accounting principles generally accepted in India.

We conducted our audit in accordance with the auditing standards generally accepted in India. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial results are free of material misstatement(s). An audit includes examining, on a test basis, evidence supporting the amounts disclosed as financial results. An audit also includes assessing the accounting principles used and significant estimates made by management. We believe that our audit provides a reasonable basis for our opinion.





We did not audit financial statements/financial information of its only subsidiary whose financial statement/financial information reflect total assets of Rs.5176.49 lakhs as at December 31, 2015, total revenues of Rs.1,498.53 lakhs and Rs 6,034.51 lakhs for the quarter and nine months ended December 31, 2015 respectively, as considered in the consolidated financial statements. These financial statements/ financial information have been audited by other auditor whose report has been furnished to us and our opinion on the consolidated financial statements, in so far as it relates to the amounts and disclosures included in respect of its subsidiary is based solely on the report of the other auditor.

In our opinion and to the best of our information and according to the explanations given to us these quarterly consolidated financial results as well as the year to date consolidated financial results:

- (i) include the quarterly financial results and year to date financial results of its only subsidiary, Pinnacle Life Science Private Limited
- (ii) have been presented in accordance with the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 in this regard; and
- (iii) give a true and fair view of the consolidated net profit and other financial information for the quarter ended December 31, 2015 and year to date consolidated results for the period from April 1, 2015 to December 31, 2015.

For GOKHALE & SATHE
CHARTERED ACCOUNTANTS
Firm Registration No.: 103264W


TEJAS. J. PARIKH
PARTNER

M. No. 123215

Place: Indore

Date: February 5, 2016.

